NCT03877796Recruiting
Clinical Pre-screening Protocol for Ovarian Cancer
Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 14 Mar 2019
- Start date
- 11 Apr 2019
- Primary completion date
- Jun 2027
- Lead sponsor
- Allarity Therapeutics
- Diseases
- Ovarian cancer
- NCT number
- NCT03877796
What you commit to
- Study type: Observational
- Planned participants: 60
- From 11 Apr 2019 to the primary completion date, Jun 2027
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
- Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Who the study is looking for
- Patients with histological confirmed epithelia ovarian cancer
- Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
- Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
- FFPE tumor tissue available
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beatson West of Scotland Cancer Centre Coordinator of this site? Confirm its status | Glasgow | United Kingdom | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| University of New Mexico Comprehensive Cancer Coordinator of this site? Confirm its status | Albuquerque | United States | Recruiting |
| Emory Winship Cancer Institute Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| University Medical Center Cancer Center Coordinator of this site? Confirm its status | Lubbock | United States | Recruiting |
| The Blavatnik Family ? Chelsea Medical Center at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| OU Health Stephenson Cancer Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
| Swedish Center for Research and Innovation Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.